Egle Therapeutics to present preclinical data on EGL-003 at 2024 Interleukin-2 Therapy Meeting

Egle Therapeutics, a biotechnology company dedicated to creating the next generation of therapies targeting regulatory T cells (Tregs) for cancer and autoimmune disorders, is set to present groundbreaking research at The Promise of Interleukin-2 Therapy meeting in Paris from September 4 to 7, 2024. The company's presentation will focus on their innovative compound, EGL-003, a novel IL-2 mutein designed to selectively expand and activate Tregs, thus enhancing therapeutic efficacy for autoimmune diseases.

The presentation, titled “EGL-003, a novel IL-2 mutein to selectively expand and activate regulatory T cells and improve therapeutic efficacy in autoimmune disease,” will provide compelling evidence regarding EGL-003’s mechanism of action. EGL-003 is a non-targeted Fc-fused IL-2 agonist mutein that binds specifically to Tregs, leading to the induction of IL-2 signaling in these cells. This selective binding and signaling result in a significant increase in Treg frequencies, as demonstrated through various in vitro studies and mouse models.

In particular, the efficacy of EGL-003 has been substantiated in a DSS-induced colitis mouse model. The treatment with EGL-003 resulted in marked improvements in clinical, macroscopic, and histological parameters, along with an expansion of tissue-resident Tregs, indicating its potential for treating autoimmune conditions.

EGL-003 represents the foremost drug candidate in Egle's pipeline targeting autoimmune diseases and has progressed to IND-enabling studies, signifying a crucial step toward clinical trials. This advancement underscores Egle Therapeutics' commitment to addressing unmet medical needs in autoimmune disorders through innovative Treg-focused therapies.

The session titled "IL-2 and Treg cell therapies" will take place on Friday, September 6, 2024, from 2:00 PM to 3:30 PM at Poster Section 4, with Poster Board Number 23. This session will provide an opportunity for attendees to delve deeper into the potential of IL-2-based therapies in modulating Treg activity and improving treatment outcomes for autoimmune diseases.

Egle Therapeutics is a biotechnology firm pioneering the development of immunotherapies that target suppressive regulatory T cells. Utilizing a proprietary discovery platform, Egle aims to identify novel Treg-specific targets and develop cutting-edge Treg-focused drug candidates for both oncology and autoimmune diseases. The company is currently advancing its leading drug candidates, EGL-001 (a Treg-selective anti-CTLA4-IL-2m) and EGL-003 (a non-targeted IL-2 Treg engager), through IND-enabling studies, with the goal of bringing these promising therapies into clinical development.

In conclusion, Egle Therapeutics' upcoming presentation at The Promise of Interleukin-2 Therapy meeting will highlight significant progress in the development of EGL-003, a novel IL-2 mutein with the potential to revolutionize the treatment of autoimmune diseases by selectively expanding and activating regulatory T cells. This innovative approach exemplifies Egle's dedication to advancing Treg-focused therapies and addressing critical gaps in the treatment of autoimmune and oncological conditions.